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Rationale: Asthma is an increasingly prevalent disease characterized by chronic airway 
inflammation and hyperreactivity, which contributes to airway obstruction and subsequent 
wheeze, cough and shortness of breath. Though asthma has a poorly understood aetiology, 
strong evidence indicates that in addition to genetic factors, the environment contributes 
substantially to disease susceptibility, especially when these exposures occur prenatally or in 
early life2. In particular, environmental exposures such as air pollution3, maternal stress4,5,6 and 
antibiotic use during pregnancy7, are associated with increased risk of childhood asthma. 
 
Antibiotics account for 80% of medications prescribed during pregnancy, and it is estimated 
that around 20-25% of pregnant women receive at least one course of an antibiotic during this 
time period8. Antibiotics are most commonly prescribed for sexually transmitted diseases, 
urinary tract or upper respiratory tract infections8, and although antibiotics are necessary in 
these situations9, the association of these medications with adverse pregnancy outcomes must 
also be considered10. It is not yet understood how antibiotics taken during pregnancy affect 
asthma susceptibility in children. If prenatal antibiotic exposure has even a small effect on 
childhood disease susceptibility, this could substantially influence public health.   
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Several observational cohorts following mother-child dyads have examined whether prenatal 
antibiotic use leads to an increased risk of childhood asthma development. Though many 
studies have been performed, a mixture of conclusions has complicated arrival at a consensus. 
Several analyses found an association between prenatal antibiotic exposure and the occurrence 
of asthma or wheeze by the age of 1011-16. Mulder (2016), on the other hand, found that general 
antibiotic use did not increase the risk of childhood asthma17. Another study found that their 
statistically significant effect regarding antibiotic use during pregnancy and risk for childhood 
asthma was confounded by adjusting for siblings that had not been foetally exposed18. Due to 
this disagreement between studies, a meta-analysis is indeed called for to assess all the 
literature that is currently available.  
 
A strong link has been observed between the intestinal microbiome, antibiotic use and asthma 
risk. The neonatal microbiome plays an important role in the development of the child's 
immune system, and it has been indicated that prenatal antibiotic treatment disrupts both the 
maternal and the neonatal microbiome, which in turn may disrupt the neonate's immune system 
development. Poor immune system development leads to lower immune tolerance, which is 
associated with an increased risk of asthma.19-21. This is an important finding, because it has 
been shown that even short-term antibiotic treatment can have a long-lasting impact on the 
human microbiome22, meaning that prenatal, or even pre-conceptional antibiotic use might also 
impact childhood health. Studies have shown that intrapartum antibiotics as well as the method 
of birth may also have an impact on the gut microbiota during the first year of life23. 
 
Since asthma prevalence is increasing globally, it is important reach a statistically sound 
conclusion regarding the possible causes, in order to provide healthcare professionals with the 
data they need to inform their patients. Therefore, we aim to conduct a robust systematic review 
and meta-analysis of all available evidence to determine the relationship between prenatal 
antibiotic exposure and the subsequent risk of childhood asthma.  
 
Objectives: The objective of this protocol is to define the methods for a systematic review to 
assess the impact of prenatal antibiotic exposure on relative risk of developing childhood 
asthma. The specific review question to be addressed in this protocol and the following 
systematic review is as follows: 
 
Do children who were exposed to antibiotics prenatally have an increased risk of developing 
asthma? 
 
Population: All pregnant women who used antibiotics during their pregnancy. 
Exposure: Antibiotics used during pregnancy. 
Comparator: Antibiotic-free pregnancy. 





Participants: We will include studies following mothers of any age and their delivered babies.  
 
Intervention: Of interest is the use of any antibiotic (prescription or self-prescription), or 
antibiotics at any time point during pregnancy, with no limit to the number of antibiotic courses 
taken by the mother. We will exclude any studies that have shared antibiotic and antifungal or 
antiviral drug administration.  
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Comparators: The main control group will include children from healthy mothers -not 
asthmatic or genetically predisposed to asthma- with no familial relation to the study group 
(i.e. no sibling comparison) who did not take antibiotics during pregnancy. If data are reported 
separately, we will include studies examining children from the same parents as the study case, 
but who were not exposed to prenatal antibiotics. 
 
Outcome: The primary outcome of the included studies will be asthma in children from birth 
to 5 years of age. Secondary outcomes will be other allergic diseases: atopic dermatitis, allergic 
rhinitis, IgE mediated immediate type allergy and food allergy in children from birth to 5 years 
of age. We will extract outcomes in all data forms (e.g. dichotomous, continuous) as reported 
in the studies. 
 
Study designs: All observational studies - analytical studies such as pro- and retrospective 
cohort studies and follow-up studies will be included. Narrative reviews will be excluded, as 
well as descriptive studies such as population studies. 
 
Time frame: We will include studies wherein the intervention has been administered at any 
trimester in pregnancy and where the follow up of the children was recorded for at least 5 years. 
Studies from the 1946 until the present day will be included. 
 
Setting: There will be no restrictions by type of setting. i.e. geographical location or 
socioeconomic status of the mothers. 
 
Information sources. Search strategies were developed using a combination of medical 
subject headings (MeSH) and keywords related to our population (pregnant women), exposure 
(antibiotics), and outcome (asthma and other atopic diseases) topics with Boolean operators. 
The search strategy was designed in MEDLINE (Ovid) and then adapted to other databases. 
The search strategy uses terms derived from initial scoping searches and expertise in the subject 
area.  
  
We will use the following databases: 
 
Table 2. Databases and information sources to be searched. 
Database/Information Source Interface/URL 
MEDLINE Ovid 
EMBASE Ovid 
Proquest Disertations and Theses A&I (grey 
literature) 
Proquest 
Cochrane central register of controlled trials Central 
 
Search strategy 
No limits on study design, date or language will be imposed on the search beyond that of the 
databases themselves.  Studies in English, German, French, Dutch, or Arabic will be included 
in the review. Only quantitative studies will be sought, descriptive papers such as narrative 
reviews will be excluded.  
 
The search strategy for MEDLINE using the Ovid interface is presented in table 2. 
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Table 2: Search strategy for MEDLINE (Ovid). ti = title, kw= author keywords, ab= abstract, 
exp = explode 
 
Maternal Exposure/ or Pregnancy/ or Prenatal Exposure Delayed Effects/ or Prenatal Care/ 
(maternal or prenatal or gestatio* or pregnan* or perinatal or antenatal).ti,kw,ab. 
1 or 2 
exp Anti-Bacterial Agents/ 
(anitbact* or anti$infecti or anti$micro or bacteriostat* or bactericid*).ti,kw,ab. 
4 or 5 
exp Asthma/ or exp Hypersensitivity/ 
(asthma* or allerg* or respiratory hypersensitivity or hypersensitivity or wheez* or AHR or atopy 
or atopic dermatitis or eczema or allergic rhinitis or IgE).ti,kw,ab. 
7 or 8 




Data management: Literature references will be managed via Endnote; the preferred software 
for managing systematic review bibliographies and de-duplicated using EndNote’s algorithms. 
Additionally, literature search results will be uploaded to Distiller Systematic Review (DSR) 
Software (Evidence Based Partners, Ottawa, Canada), a programme that facilitates coordinated 
paper screening and data extraction.  
  
Selection process: Two independent reviewers will examine the title and abstract of the studies 
found in the search results, and will remove irrelevant studies. Next, a second selection will be 
performed by examining the full text of the articles and carefully applying the eligibility criteria 
to determine inclusion. In case of exclusion, the reason will be recorded. In the case that a 
conflict arises, the paper in question will be discussed with a third reviewer.  
 
Data collection process: For each eligible study, two researchers will extract the data 
independently and in duplicate using carefully constructed forms in DistillerSR. Additionally, 
to avoid any inconsistency between the reviewers a collaboration exercise will be conducted 
before the extraction of data.  
 
The abstract of the data will contain the intervention type and all of the desired outcomes. Any 
disagreement will be resolved through discussion or through one of our two arbitrators. In case 
of any uncertainty, we will contact the study authors.  
  
Data items. The following data will be extracted and summarized:  
i. Study ID: authors, title, year and journal 
ii. Study design characteristics: sample size for control and treated groups 
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iii. Detailed description of exposure:  antibiotics used, their dosage and dosage form, 
duration of the treatment and the cause of prescription, duration of the follow up, and 
which other types of drugs were used during pregnancy. 
iv. Disease characteristics in offspring: type of diagnosis, method of diagnosis, age of 
diagnosis 
v. Outcome measures: Type of effect size e.g. RR/OR/SMD/r etc, 95% CI, p-value, r, 
confounding factors  
 
Information will be extracted from all articles determined to be relevant by the screening 
process. If necessary data is missing, we will contact the authors for additional data.  
 
Outcomes and prioritization. The main outcome will be childhood asthma in a child aged 0-
5, defined as either 1) an asthma diagnosis by a doctor; 2) a report of two or more of the 
following symptoms: 
 Wheeze 
 Shortness of breath or heavy breathing 
 Cough 
 Chest tightness, especially for >10 days during Upper Respiratory Tract Infection 
(URTI) with  
o > 3 episodes per year or  
o severe episodes or night worsening,  
without showing one of the following: 
o Isolated cough with no other respiratory symptoms 
o Chronic production of sputum 
o Shortness of breath associated with dizziness, light-headedness or peripheral 
tingling (paraesthesia) 
o Chest pain 
o Exercise-induced dyspnoea with noisy inspiration 
or 3) a confirmed or documented variable expiratory airflow limitation.  
‘Variable’ refers to improvement and/or deterioration in symptoms and lung function. 
Excessive variability may be identified over the course of one day, from day to day, from visit 
to visit, or seasonally, or from a reversibility test. 
 
Subgroup analysis. Subgroup analysis will be performed to assess potential sources of data 
heterogeneity based on the following:  
 
1. Impact of prenatal antibiotic exposure on secondary outcomes, i.e. other atopic diseases 
i. atopic dermatitis  
ii. allergic rhinitis 
iii. IgE mediated immediate type allergy  
iv. food allergy 
2. Is antibiotic administration during a specific trimester associated with a higher 
likelihood of developing asthma during childhood? 
3. Are specific antibiotic types (i.e. gram-positive spectrum, gram-negative spectrum and 
anaerobic spectrum antibiotics) associated with a higher likelihood of developing 
asthma during childhood? 
4. Is the impact of antibiotics on the risk of developing childhood asthma dose dependent? 
5. Does the route of administration have an impact on the effects of the antibiotic? 
6. Is the type of infection in the mother related to the severity of asthma in offspring? 
7. Is the severity of asthma in the offspring dependent on the sex of the child?  
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8. What is the impact of time (year of study) on the association between antibiotics and 
childhood asthma?  
 
Risk of bias in individual studies: The potential studies to be included in the meta-analysis 
will be evaluated for the risk of bias, using the Newcastle-Ottawa Quality Assessment Scale 
(NOS) for cohort studies. Each study will be assessed by two independent reviewers, for 
criteria including the selection of the study populations, the comparability between the cohorts 
and the outcome of interest. The studies will be awarded a maximum of 9 points each, 
depending upon the fulfilment of the specific criteria. Studies will be eligible for inclusion in 
the meta-analysis if they are scored at least 6 points or more. If any disagreements between the 




Study criteria for quantitative synthesis: The quantitative synthesis will include all studies 
that report at least one measurement of one predictor and one outcome variable. Additionally, 
data will only be integrated when it was collected under ethically sound conditions, and when 
sufficient and reliable information for the measurement instrument and protocol was provided 
in the study.  
  
Data handling and combining: Since simply averaging effect sizes or pooling data can result 
in incorrect estimations of standard errors and false test statistics24, we will apply a meta-
analytic model to the data. A first choice for a meta-analytic summary is the aggregate level on 
which to conduct the analysis. Models with individual participant data can either be calculated 
from all participant data of all studies in one step (one-stage), or with data aggregates from 
each study (two-stage). Except for uncommon cases or very large datasets, both designs 
produce comparable results and can be specified to result in quasi-identical values25,26. We 
expect differences in the collected studies, and plan to conduct the meta-analysis on aggregated 
data from each study. 
 
On the aggregate level, effect sizes of outcomes will likely be reported as log OR (Odds Ratio) 
or log HR (Hazard Ratio) with the corresponding variance. Since these outcome types are not 
interchangeable, the aggregation will possibly include calculating the respective outcome types 
from within-study data. If individual data was not reported, we will transform HR into OR (or 
OR into HR) according to Shor et al. (2017)27, Zhang and Yu (1998)28 and Van der Weele, 
(2019)29. If the predominant outcome type is HR, a back-transformation is necessary before 
entering the data into the meta-analytic model to account for typical skewness and asymmetry 
of the HR. 
 
The aggregated data will then be entered into a multivariate meta-analytic regression model, 
which controls for correlation between predictors. Both random- and fixed-effects models will 
be estimated with REML in the metafor package for r30. This package provides different 
estimation techniques, such as Peto’s one-step method, the conditional logistic model and the 
Mantel-Haenszel method according to Rothman et al. (2008)31. Here, the choice depends much 
on the empirical data. Additional subgroup analysis will be conducted to check for moderation 
effects (e.g. trimester, type of antibiotic). 
 
To address variance between studies, heterogeneity will be calculated with the Q- and I2-
statistic32. In combination with a power-analysis approach as described by Valentine, Pigott 
and Rothstein (2010)33, this allows for precise interpretation. 
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Proposed additional analyses: In addition to the meta-analytic model described above, 
sensitivity analysis will be carried out. To check for publication bias, a contoured funnel-plot 
will be constructed. Further outlier analysis will firstly be based on effect sizes and variances 
and secondly consist of Viechtbauer and Cheung’s outlier battery, which is implemented in the 
metafor package for r. 
 
If meta-analytic models cannot be estimated, a descriptive table with all study results will be 
provided.  
 
Confidence in cumulative evidence: The strength of evidence for all outcomes will be judged 
using the Tool to Assess Risk of Bias in Cohort Studies, contributed by the CLARITY Group 
at McMaster University. The quality of the evidence will be assessed across seven domains: 
selection of exposed and non-exposed cohorts; assessment of exposure; outcome of interest; 
prognostic factors; assessment of outcome; follow up; co-interventions. Each study will receive 





This systematic review and metanalysis will synthesize current evidence surrounding the 
impact of gestational antibiotic exposure on childhood atopic disease. The results of this review 
will aid in understanding the risks associated with antibiotics prescribed during pregnancy and 
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